News

The current Phase 2 AbGn-168H trial will be a multicenter, placebo-controlled, double-blind trial with the primary objective to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect

PerkinElmer Informatics general manager Michael Stapleton said as chemists are turning to electronic laboratory notebooks to plan, execute and record their experiments, they also need ready access to

Previously, FDA has also approved the company’s ANDA for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg/500mg and 15mg/850mg. The FDA has granted Mylan 180 days of generic marketing

The ¥4.2bn ($53m) building is expected to improve Astellas’ capacity to manufacture investigational drug substance used in high pharmaceutical activities. The Building No. 8 will have seven stories

The patent covers the methods and compositions to treat cancer using oncolytic Respiratory Syncytial Virus or (RSV) activity. The agreement, in conjunction with the US and worldwide patents

As part of the collaboration, the companies will develop TGR-1202 on a worldwide basis, excluding India, in the areas of hematologic malignancies and autoimmune disease. Rhizen will also

The Phase 1 dose-ranging study of LX2931, which was designed to explore higher doses of LX2931 in patients with rheumatoid arthritis, involved 10 patients eight of whom were

According to the company, the verdict reiterates the Court’s earlier decision rendered on 29 July 2011. Myriad Genetics president and CEO Peter Meldrum said Myriad Genetics is pleased

The certification will allow WuXi to carry out non-clinical laboratory studies with respect to the requirements of the Chinese Food and Drug Act and SFDA GLP regulations. The